CNBX Pharmaceuticals Inc (CNBX) is a clinical-stage pharmaceutical company developing cannabinoid-derived drug candidates for cancer treatment. The company generates no product revenue as of the fiscal year ended August 31, 2025, operating entirely in the research and development phase. Its pipeline centers on RCC-33, a synthetic cannabinoid-based formulation targeting colorectal cancer as a neoadjuvant therapy, and Cannabics CDx, an ex-vivo drug sensitivity test designed to guide cannabinoid therapy selection for cancer patients. Chemistry, manufacturing, and controls work is fully outsourced, with Purisys identified as a planned supplier of GMP-grade active pharmaceutical ingredients for anticipated Phase I/II clinical studies. CNBX has not established sales, marketing, or distribution infrastructure. The company carries an accumulated deficit, holds convertible loan obligations, and has amounts due to a related party, reflecting a balance sheet typical of a pre-revenue drug development entity. The company is also developing Cannabics SR, a dietary supplement subject to FDA and FTC regulation in the United States and Ministry of Health oversight in Israel.

Revenue model

No product revenue is disclosed in the fiscal year ended August 31, 2025 filing. The company is pre-commercial, funding operations through capital raises rather than product sales.

Products and services

RCC-33: synthetic cannabinoid-based drug candidate targeting colorectal cancer via neoadjuvant therapy. Cannabics CDx: ex-vivo drug sensitivity test for identifying effective cannabinoid combinations in cancer patients. Cannabics SR: dietary supplement subject to FDA, FTC, and Israeli Ministry of Health regulation.

Customers and end markets

End market is oncology, specifically colorectal cancer treatment. Intended customers are healthcare providers and cancer patients. No commercial customers are disclosed as of August 31, 2025.

Value-chain role

Drug discovery and development company. Outsources all chemistry, manufacturing, and controls to contract suppliers including Purisys for GMP-grade APIs. Has not established downstream sales or distribution. Pursues patent and trademark protection for drug candidates and processes.

Geographic exposure

United States primary regulatory jurisdiction via FDA and DEA. Israel identified as an additional regulatory jurisdiction for dietary supplement products via Ministry of Health.

Source: SEC 10-K, filed 2025-12-01

Industry: Pharmaceutical Preparations Peers: APOLLO BioWellness Inc NEXIEN BIOPHARMA, INC. Johnson & Johnson GRI Bio Inc